Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
